Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived CAR-T cells and HSCT for R/R B-cell leukemia
NCT03463928Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2017
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of tanCART-19/22 and CD19-directed CAR-T cells in B-cell leukemia (BCL) and B cell lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoint: Number of Participants with Severe/Adverse Events at 24 weeks. Status: unknown.
02
Drugs
tanCART-19/22CD19-directed CAR-T cells
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT03463928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463928.